A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 521 participants.
Also called NCT04109547
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 521 participants
- Sponsor
- Registry
-
NCT04109547 -
2018-002590-22
-
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, China, Hungary, Serbia, Taiwan, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04109547. Randomized; quadruple masking; primary purpose treatment. Start 2019-10-01 (actual); primary completion 2021-09-23 (actual). Results posted on 2023-09-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
- Acronym
- PIONEER 11
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Oral semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04109547- Content hash
27b722b3ffd3f82434312370808209c79ed1539ce41780342f5dd660358fbe09